Lisa Hamilton, a jeweler and doula in Brooklyn, NY, knows about the side effects. She recently tried CBD for the shoulder pain that plagued her five years after an accident. Her doctor certified that she was in chronic pain, which under New York State law allowed her to buy from a state dispensary. One Friday, she swallowed two 10-mg capsules, the amount recommended at the dispensary, then took another two on Saturday. “By Sunday, it felt like I’d gotten hit by a truck. Every muscle and joint ached,” Hamilton says. She cut back to one pill a day the following week, but still felt hungover. She stopped after that.
As the oil is in liquid form it can be consumed orally without smoking and can be easily administered to ailing children and adults for whom it is prescribed as medication. Though hemp plant is used for several industrial products and also as biofuel, the seeds and flowers of the plant are used to produce oil that is an active ingredient in several medical therapies for humans and animals.
The appeal? Proponents claim CBD can help ease pain, anxiety, depression and stress, boost focus and productivity, improve the immune system, reduce inflammation and more. And – unlike its psychoactive cousin THC – CBD, they say, is harmless, legal and can't get you high. "The known is it's good for you, it helps a lot of people and a lot of things, and you can't hurt yourself," says Phil Asquith, a farmer and producer of extra-virgin olive oil in California, who founded one of the first companies in the CBD space. "The unknown is all the details."
First, ethanol is a polar solvent. This means that it will readily mix with water and dissolve water-soluble molecules. This creates a great challenge for companies using the ethanol extraction method because chlorophyll is one of the compounds that will easily co-extract. Chlorophyll in the concentrate will result in a dark green coloring and an unpleasant bitter, grassy flavor.
Zuardi, A. W., Crippa, J. A., Hallak, J. E., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., … & Guimarães, F. S. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation [Abstract]. Current Pharmaceutical Design, 18(32), 5,131–5,140. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22716160